Abstract

Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19

J Crohns Colitis. 2020 Oct 21;14(Supplement_3):S769-S773. doi: 10.1093/ecco-jcc/jjaa135.

Corey A Siegel 1, Britt Christensen 2, Asher Kornbluth 3, Joel R Rosh 4, Michael D Kappelman 5, Ryan C Ungaro 3, Douglas Forsyth Johnson 6, Scott Chapman 7, David A Wohl 8, Gerassimos J Mantzaris 9

 
     

Author information

  • 1Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock IBD Center, Lebanon, NH, USA.
  • 2Gastroenterology Department, Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • 3Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • 4Division of Pediatric Gastroenterology, Goryeb Children's Hospital, Morristown, NJ, USA.
  • 5Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • 6Departments of Infectious Diseases and Internal Medicine, Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • 7Department of Infectious Diseases, St Vincent's Hospital, Sydney, NSW, Australia.
  • 8Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • 9Department of Gastroenterology, Evaggelismos-Ophthalmiatreion Athinon-Polykliniki GHA, Athens, Greece.

Abstract

Patients with inflammatory bowel diseases [IBD] are frequently treated with immunosuppressant medications. During the coronavirus disease 2019 [COVID-19] pandemic, recommendations for IBD management have included that patients should stay on their immunosuppressant medications if they are not infected with the severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], but to temporarily hold these medications if symptomatic with COVID-19 or asymptomatic but have tested positive for SARS-CoV-2. As more IBD patients are infected globally, it is important to also understand how to manage IBD medications during convalescence while an individual with IBD is recovering from COVID-19. In this review, we address the differences between a test-based versus a symptoms-based strategy as related to COVID-19, and offer recommendations on when it is appropriate to consider restarting IBD therapy in patients testing positive for SARS-CoV-2 or with clinical symptoms consistent with COVID-19. In general, we recommend a symptoms-based approach, due to the current lack of confidence in the accuracy of available testing and the clinical significance of prolonged detection of virus via molecular testing.

© Copyright 2013-2020 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.